Clinical Trial Update: BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

View source ↗

Summary

A completed clinical trial update studying BRAF and MEK inhibition with dabrafenib and trametinib in melanoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: EuMelaReg gGmbH | Conditions: Melanoma | Status: COMPLETED